U.S. Life Sciences Stock News

If you are wondering whether V2X at around US$70.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stock has returned 4.5% over the last 7 days, 3.1% over the last month, 27.7% year to date and 55.0% over the past year, which naturally raises questions about what is already baked into the current price. Recent coverage has focused on V2X as a capital goods company listed on the NYSE under the ticker VVX. Investors are paying close attention to how it...

If you are wondering whether TransDigm Group's current share price fairly reflects the business, this article is designed to help you think through that question step by step. The stock last closed at US$1,316.26, with returns of 1.6% over 7 days, a 7.8% decline over 30 days, a 3.1% decline year to date, 2.6% over 1 year, 99.9% over 3 years and 161.2% over 5 years. Recent share price moves sit against a backdrop of ongoing interest in TransDigm Group as a major US capital goods name...

Sionna Therapeutics (SION) is back on traders’ radar after a recent share price pullback, with the stock down about 20% over the past month and around 13% over the past 3 months. See our latest analysis for Sionna Therapeutics. Those recent declines come after a very strong run, with a 1 year total shareholder return of about 135% and a current share price of US$33.92. This suggests momentum has cooled as investors reassess growth potential and risk around the CF pipeline. If Sionna’s swings...

If you are looking at Medical Properties Trust and wondering whether the current share price reflects its underlying worth, you are not alone. The stock closed at US$5.65 recently, with returns of 12.5% over the last 30 days, 11.2% year to date and 4.4% over the past year, set against longer term 3 year and 5 year returns of 28.9% and 60.3% declines. Recent headlines around Medical Properties Trust have focused on its balance sheet, portfolio repositioning and how it is responding to a...

CareTrust REIT (NYSE:CTRE) has moved into the UK healthcare real estate market through the acquisition of Care REIT plc. The transaction expands CareTrust REIT's portfolio and marks its first international platform outside the US. The company has also scaled its structured finance activities alongside large portfolio acquisitions. CareTrust REIT is taking a bigger swing with this UK entry, adding a new geography on top of its existing US footprint. The stock last closed at $40.89, with a 1...

Winnebago Industries (NYSE:WGO) is working through persistent RV industry headwinds as sales have fallen over the past two years. Despite reporting revenue growth, the company has seen profitability weaken, pointing to rising pressure on its core business. This combination of softer sales trends and thinner margins is drawing attention to deeper challenges across the recreational vehicle sector. For you as an investor, Winnebago sits at the intersection of discretionary spending and outdoor...

In February 2026, Tronox Holdings plc reported fourth-quarter 2025 sales of US$730 million and a net loss of US$176 million, with full-year 2025 sales of US$2.90 billion and a net loss of US$470 million, before subsequently filing an omnibus shelf registration for ordinary shares, preference shares, and debt securities. The combination of widening losses and a new universal shelf registration highlights Tronox’s need for financial flexibility at a time of rising earnings pressure and...

Kosmos Energy (NYSE:KOS) has secured extensions for major Ghana oil and gas licenses to 2040. The company is reshaping its portfolio, including acquiring a key FPSO, exiting Equatorial Guinea assets, and focusing on the Gulf of Mexico via a new alliance with Shell. Management is targeting a 20% reduction in operating costs and a 10% reduction in net debt in 2026, supported by new bond financing. Kosmos Energy, trading at $2.4, has seen sharp share price swings, with the stock up 16.5% over...

Why EnerSys is on investors’ radar EnerSys (ENS) has drawn attention after recent trading reflected a mix of short term pressure and longer term strength, prompting investors to reassess how its current share price lines up with recent returns. See our latest analysis for EnerSys. At a share price of $165.97, EnerSys has seen some recent pressure, including a 7.89% 1 month share price return. However, its 14.68% 3 month share price return and 69.60% 1 year total shareholder return point to...

SiriusPoint Ltd. has reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$973.7 million and net income reaching US$244 million, while full-year revenue climbed to US$3.21 billion and net income to US$459.6 million, alongside sharply higher earnings per share from continuing operations. On the same day, the Board of Directors announced it will consider a share repurchase program, a move that could meaningfully influence capital allocation, per-share...

In late February 2026, FIGS, Inc. reported fourth-quarter 2025 revenue of US$201.9 million and net income of US$18.51 million, capping a full-year performance of US$631.1 million in sales and US$34.25 million in net income with sharply higher earnings per share versus 2024. Management paired these results with an outlook for 10% to 12% revenue growth in 2026, underscoring momentum from a larger active customer base, international expansion and improved operating margins. We’ll now examine...

In late February 2026, California Water Service Group reported that fourth-quarter 2025 sales eased to US$219.98 million and net income fell to US$11.48 million, with full-year 2025 sales of US$1,000.14 million and net income of US$128.21 million, reflecting lower water consumption and higher costs. At the same time, the company accelerated its expansion by agreeing to acquire Nexus Water Group’s Nevada and Oregon systems and the remaining interest in its Texas joint venture, while...

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...

Hawaiian Electric Industries reported full-year 2025 revenue of US$3.09 billion, down slightly from US$3.22 billion in 2024, while swinging from a very large net loss to net income of US$123.12 million, or US$0.71 in basic and diluted earnings per share from continuing operations. The earnings rebound coincided with progress on Maui wildfire-related settlements, funded by insurance, and regulatory approval of a multi-year wildfire safety plan that supports both risk reduction and grid...

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...

Why AES (AES) is on investors’ radar today AES (AES) is drawing attention after a mixed run in its share price, with a 1 day return of around 0.18% and a past 3 months total return of about 1.79%. Over the past year, the stock’s total return of roughly 34.25% contrasts with weaker multi year figures. At the same time, annual revenue of about US$12.1b and net income of roughly US$1.1b frame the current debate around valuation and business momentum. See our latest analysis for AES. That sharp 1...

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

Earnings, guidance and new buyback put Expro Group Holdings (XPRO) in focus Expro Group Holdings (XPRO) is back on investors’ radar after releasing fourth quarter and full year 2025 results, setting 2026 revenue guidance, and unveiling a new US$100 million share repurchase plan. The latest numbers give you a fresh look at how the business ended 2025. The guidance and buyback outline how management is thinking about the next phase. Here is what stands out from the announcement and how you...

Harrow (NasdaqGM:HROW) has introduced a new Direct-to-Prescriber PharmaPack offering focused on post-cataract surgery care. The PharmaPack kits provide access to FDA-approved ophthalmic products and are designed to be ordered directly by eye care providers. The launch aims to reduce reliance on off-label compounded formulations and support more standardized treatment protocols. For investors following ophthalmic therapeutics, Harrow sits at the intersection of branded eye care drugs and...

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...

In late February 2026, Virtu Financial reported Q4 2025 results showing its highest quarterly adjusted net income since early 2021, supported by elevated market volatility and strong trading volumes across both Market Making and Execution Services. An interesting angle for investors is Virtu’s plan to channel this momentum into higher trading capital, upgraded infrastructure, and moves into emerging areas such as prediction markets and crypto. We’ll now explore how this stronger quarter,...